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ABSTRACT: The cyclic acyldepsipeptide (ADEP) antibiotics
are a new class of antibacterial agents that kill bacteria via a
mechanism that is distinct from all clinically used drugs. These
molecules bind and dysregulate the activity of the ClpP
peptidase. The potential of these antibiotics as antibacterial
drugs has been enhanced by the elimination of pharmaco-
logical liabilities through medicinal chemistry eﬀorts. Here, we
demonstrate that the ADEP conformation observed in the
ADEP−ClpP crystal structure is fortiﬁed by transannular
hydrogen bonding and can be further stabilized by judicious
replacement of constituent amino acids within the peptidolactone core structure with more conformationally constrained
counterparts. Evidence supporting constraint of the molecule into the bioactive conformer was obtained by measurements of
deuterium-exchange kinetics of hydrogens that were proposed to be engaged in transannular hydrogen bonds. We show that the
rigidiﬁed ADEP analogs bind and activate ClpP at lower concentrations in vitro. Remarkably, these compounds have up to 1200-
fold enhanced antibacterial activity when compared to those with the peptidolactone core structure common to two ADEP
natural products. This study compellingly demonstrates how rational modulation of conformational dynamics may be used to
improve the bioactivities of natural products.
■ INTRODUCTION
Among the most interesting antibacterial drug targets to
emerge in the past decade is the proteolytic complex formed by
ClpP (caseinolytic peptidase) and its AAA+ partners (ATPases
associated with diverse cellular activities). ClpP is a highly
conserved peptidase that is involved in the turnover of a wide
variety of cellular proteins, including transcription factors that
regulate virulence-factor production and stress responses.1−5
To form the catalytically active peptidase, ClpP monomers self-
assemble into heptameric rings that stack face-to-face to form a
barrel-shaped tetradecamer.6−8 The “barrel” encloses a solvent-
ﬁlled chamber that is decorated with fourteen serine protease
active sites and, in principle, is large enough to accommodate a
50 kDa protein.6−8 However, narrow axial pores at each end of
the barrel prevent entry of folded proteins into the proteolytic
chamber.6−8 In fact, only small peptides with 6 or fewer amino
acids may freely diﬀuse into the ClpP proteolytic chamber and
be degraded. In the degradation of folded proteins, ClpP
functions in conjunction with AAA+ partners like ClpA, ClpX,
and ClpC that recognize, unfold, and coaxially translocate
substrates into the proteolytic chamber.9−12 These accessory
ATPases play critical roles in regulating the activity of ClpP.
Genetic studies have established that the clpP gene and genes
encoding the AAA+ partners are essential for virulence in some
pathogenic bacteria (e.g., Staphylococcus aureus, Listeria
monocytogenes, and Streptococcus pneumoniae) and for viability
in others (e.g., Mycobacterium tuberculosis).13−20 Although no
drugs that target ClpP have been introduced into the clinic yet,
the critical physiological roles of ClpP make it an attractive
target for the development of antibacterial agents.
Several molecules reported to perturb ClpP activity have
been discovered in high-throughput screens or in mechanistic
investigations of natural products with antibacterial activ-
ity.13,14,23 These compounds are classiﬁed as either activators or
inhibitors of ClpP. Treatment of bacteria with inhibitors of
ClpP phenocopies the eﬀects of clpP null mutations (i.e.,
compromised virulence or viability),21,22 whereas bacteria are
killed upon exposure to ClpP activators.23 The ﬁrst ClpP
activators to be reported were the cyclic acyldepsipeptide
antibiotics (ADEPs).24,25 The representative members of this
group of antibiotics are “A54556A and B” produced by
Streptomyces hawaiiensis24 and enopeptins A and B produced by
Streptomyces sp. RK-1051 (Figure 1).25 Collectively, the ADEPs
have been reported to exhibit potent activity against a broad
range of Gram-positive bacterial pathogens, including S. aureus,
S. pneumoniae, Enterococci, and M. tuberculosis.24−29 As reﬂected
by the fact that no clinically used antibacterial drugs target
ClpP, the ADEPs have activity against multidrug resistant,
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pathogenic bacteria observed in clinical and community
settings.26,29
Structural studies indicate that the ADEPs bind at the
subunit interfaces of the ClpP tetradecamer, which also serve as
docking sites for the accessory ATPases.30,31 A consequence of
this competitive binding is expansion of ClpP’s axial
pores.26,30−32 Remarkably, these ADEP-induced changes in
ClpP’s quaternary structure enable it to degrade oligopeptides
and unstructured or nascent proteins without the intervention
of the accessory ATPases. The indiscriminate degradation of
cellular proteins like the essential cell-division protein, FtsZ, by
ADEP-activated ClpP underlies the antibiotics’ toxicity.33 With
respect to mechanism, the ADEPs are unique because most
antibiotics inhibit rather than activate their targets.
The eﬃcacy of ADEPs at killing pathogenic bacteria and
their peculiar mode of action have prompted eﬀorts to assess
their medicinal potential. Initially, the natural products were
found to be inactive in mouse models of systemic S. aureus
infection, despite their potent antibacterial activity in vitro.29
Their pharmacokinetic proﬁles were characterized by poor
water solubility, rapid systemic clearance, and chemical
instability. At Bayer Healthcare AG, a medicinal chemistry
program was established to optimize the structures of the
ADEPs in ways that would enhance their stability and biological
activity.29 A compound called ADEP-4, which had 160-fold
greater potency and more chemical stability than the natural
products, emerged from their optimization program. It diﬀers
from enopeptin A and A54556A in three ways (Figure 1).29
First, it has a more chemically stable heptenoyl moiety in place
of the conjugated polyenes. Second, rather than phenylalanine
in its appendant side chain, ADEP-4 has a 3,5-diﬂuoropheny-
lalanine, which was credited with improving compound
bioavailability and binding to ClpP. Finally, the natural
ADEPs have a N-methylalanine residue within the core
macrocycle, whereas ADEP-4 has a cyclic amino acid,
pipecolate (a six-membered ring), at the same position. The
last feature was particularly important for enhancing potency.
Accordingly, it was proposed that the incorporation of the
pipecolate residue rigidiﬁes the ADEP peptidolactone, thereby
reducing the entropic cost of ClpP binding.29 This rigidifying
structural feature must enforce a speciﬁc conformation that is
compatible with ClpP binding, as evidenced by the inactivity of
an ADEP analog with a proline residue (a ﬁve-membered ring)
in place of N-methylalanine.34 In addition to potent activity in
vitro against S. aureus, S. pneumoniae, and Enterococci,29 ADEP-4
and close analogs are reported to be toxic to M. tuberculosis in
vitro, particularly in combination with eﬄux pump inhibitors.28
Importantly, ADEP-4 has impressive activity in vivo. In fact,
mice with potentially lethal infections of S. aureus were cured by
via intravenous administration of ADEP-4.29 Recently, it has
been reported to completely eradicate S. aureus bioﬁlms in vitro
and in mouse models of chronic infection when coadministered
with the antibacterial drug rifampicin.35
In a previous study,27 we investigated the consequences of
replacing amino acids in the ADEP macrocycle with more
conformationally constrained residues. One of the compounds
that we prepared was an analog of ADEP-4 with 4-
methylpipecolate in place of the pipecolate. The methyl
substituent was predicted to further restrict the conformational
ﬂexibility of the pipecolate and by extension that of the
peptidolactone. The compound with 4-methyl pipecolate was
2- and 4-fold more potent than ADEP-4 against clinical isolates
of methicillin-resistant S. aureus and vancomycin-resistant
Enterococcus faecalis, respectively.27 Motivated by these initial
ﬁndings, we sought to study the phenomenon of restricting
peptidolactone conformation and deﬁne its impact on the
ADEPs’ binding to and activation of ClpP and on their
bioactivity. We utilized deuterium exchange experiments with
1H NMR to empirically measure the eﬀects of various structural
modiﬁcations on peptidolactone conformational dynamics. In
Figure 1. Structures of ADEP natural products and optimized
synthetic analogs thereof.
Figure 2. Transannular hydrogen bonding in an ADEP. (A) Stereocartoon of an ADEP (gray ball-and-sticks) bound to Escherichia coli ClpP
(adjacent subunits in green and orange), generated from crystal structure 3MT6.30 Two predicted hydrogen bonds are observed within the ADEP
(black; distances in Å), and several hydrogen bond networks (cyan) occur either directly between the ADEP and ClpP or via ordered water
molecules. (B) Schematic representation of ADEP transannular hydrogen bonds. (C) Overlay of 1H NMR spectra of compound 1a over time in
CD3OD. Amides participating in bonds are highlighted in blue and the nonbonding amide is highlighted in red. The half-lives of the hydrogens of
the alanine and diﬂuorophenylalanine residues were 26.8 and 3.87 min, respectively (see Supporting Information).
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addition, enzymatic assays were used to measure the capacity of
the ADEP analogs to bind and activate ClpP. Finally, we used
bioassays to assess the toxicities of the compounds to three
species of pathogenic bacteria. It is noteworthy that some of the
rigidiﬁed ADEPs bind and activate ClpP at substantially lower
concentrations in vitro and have up to 1200-fold enhanced
antibacterial activity.
■ RESULTS AND DISCUSSION
Assessment of the Conformationally Biasing Hydro-
gen Bonds in the ADEPs. Numerous noncovalent
interactions between the ADEPs and ClpP are observed in
crystal structures of the complex.30,31 The ADEPs themselves
adopt a compact conformation that appears to be enforced by
two transannular hydrogen bonds between the peptidolactone
and the appendant side chain (Figure 2A, Table S1).
Interestingly, a similar conformation is observed in crystals of
free ADEP, where analogous hydrogen bonding between the
peptidolactone and the side chain has been predicted.29 The
similarities suggest that the free ADEPs may be predisposed to
adopt a conformation that is compatible with ClpP binding.
To test the prediction that free ADEPs exhibit intramolecular
hydrogen-bonding in solution, we performed experiments in
which 1H NMR was used to measure deuterium exchange rates
of amide hydrogen atoms predicted to participate in the bonds
(Figure 2B). Hydrogen−deuterium exchange rates have been
shown to be dependent upon the presence and strength of
intramolecular hydrogen bonds in peptides.36 Accordingly, we
anticipated that deuterium exchange rates at the amides
engaged in hydrogen bonds would be markedly slower than
at non-hydrogen-bonded amides. Given the limited solubility of
the ADEPs in water, we selected deutero-methanol (CD3OD)
as the solvent for the deuterium exchange experiments,
accepting the possibility that the molecules’ conformations
could diﬀer in organic and aqueous solvents. Immediately after
preparation of a dilute solution of ADEP 1a in CD3OD
(Figures 2B and 3), we monitored attenuation of the amide
proton resonances by 1H NMR over a period of hours at 25 °C.
As expected, the hydrogen atoms of the three secondary amides
in the ADEP exchanged with deuterium at markedly diﬀerent
rates (Figure 2B,C). The amide hydrogen of the serine residue,
which does not participate in a transannular hydrogen bond,
exchanged completely in CD3OD within several seconds and
could never be observed in a 1H NMR spectrum.
By comparison, the amide hydrogen of the side chain
diﬂuorophenylalanine residue required several minutes to
completely exchange with deuterium; whereas, that of the
alanine amide within the macrocycle exchanged over the course
of two hours (Figure 2C). These observations are consistent
with the existence of transannular hydrogen bonds that are
analogous to those inferred from the crystal structures of both
free ADEP and ADEP in complex with ClpP.29−31
Chemical Syntheses of ADEPs with Conformationally
Constrained Peptidolactones. We hypothesized that the
bioactive conformation of the ADEPs could be stabilized by
judicious replacement of particular amino acid constituents of
the peptidolactone with more conformationally constrained
analogs. First, we envisioned substituting the N-methylalanine
residue with pipecolate residues bearing C-4 substituents of
varying size. Cyclic amino acids are typically more conforma-
tionally constrained than their acyclic counterparts, and ring
substituents tend to limit ring conformational dynamics by
imposing high energetic penalties to certain conformations
(e.g., 1,3- diaxial strain). In a separate approach, we envisioned
replacing the serine residue of the macrocycle with allo-
threonine, a serine analog with a methyl substituent on the β-
carbon. This amino acid is more conformationally constrained
because the methyl group confers additional torsional strain
about both the Cα-Cβ bond and Cβ-O bond. Importantly, we
predicted that the methyl substituent of this diastereomer of
threonine would not sterically clash with ClpP.
There are multiple precedents for the chemical syntheses of
the cyclic acyldepsipeptide antibiotics and analogs there-
of.27,29,37 The desired ADEP analogs were synthesized via a
convergent strategy that was previously developed in our
laboratories (see Supporting Information).27 The key tripeptide
fragments containing pipecolate or the substituted pipecolates
were prepared using Joullie-́Ugi multicomponent reactions of
dehydropiperidines, a chiral isocyanoacetate derived from
alanine, and Boc-proline.27,38 An ADEP with a natural product
peptidolactone and an additional six ADEPs with conforma-
tionally restricted amino residues in the peptidolactone were
chemically synthesized (Figure 3).
Measurement of ADEP Peptidolactone Dynamics via
1H NMR Deuterium Exchange. With the desired ADEPs in
hand, we sought to examine the relative rigidities of the
peptidolactones empirically. We anticipated that the deuterium
exchange rates for the hydrogens of the amides engaged in the
hydrogen bonds would be dependent on the conformational
freedom of the ADEP peptidolactone. For all seven ADEPs, the
alanine amide hydrogens’ half-lives in CD3OD were calculated
from the rates at which their resonances in 1H NMR spectra
attenuated relative to those of a nonexchanging reference signal
in the same spectra (Figure 4; Table 1). Compound 1a, a
known molecule29 that is the closest analog of the natural
product enopeptin B with N-methylalanine and serine residues
in its peptidolactone, was expected to have the least rigid
Figure 3. Library of ADEP analogs. The N-methylalanine, pipecolate,
4-methylpipecolate and 4-isopropylpipecolate residues are highlighted
in red. Serine and allo-threonine residues are highlighted in blue.
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macrocycle and thus served as a point of comparison for the
other ADEPs.
Using deuterium-exchange experiments, we systematically
assessed the conformational consequences of replacing the N-
methylalanine and serine residues in the ADEP macrocycle with
conformationally constrained pipecolate and allo-threonine
residues, respectively (Figure 4). Interestingly, the pipecolate
moiety does not fortify both of the transannular bonds that are
apparent in compounds containing N-methylalanine (com-
pounds 1a and 1e). Indeed, we found that the amide hydrogen
of the diﬂuorophenylalanine of compound 1b exchanged
completely within seconds in CD3OD, whereas the analogous
hydrogen in compound 1a had a half-life of 3.87 min (see
Supporting Information). Apparently, with the pipecolate
residue in the macrocycle, the potential donor and acceptor
atoms of the hydrogen bond are either too far apart or do not
have appropriate trajectories for bonding. In contrast, the
transannular hydrogen bond in which the alanine residue is the
donor is retained in all of the ADEPs and strengthened by the
presence of conformationally constrained amino acids within
the macrocycle. For instance, compound 1b harboring a
pipecolate residue in the peptidolactone had a slower rate of
deuterium exchange rate than 1a. Further, we found that the
deuterium-exchange rate decreased as the steric bulk of the C4
substituent on the pipecolate increased (see data for
compounds 1b, 1c, and 1d in Figure 4). Replacement of the
native serine residue in the ADEP peptidolactones with allo-
threonine profoundly slowed the deuterium-exchange rate. For
instance, the half-lives of the alanine amide hydrogens in
compound 1a, which has serine, and compound 1e, which has
allo-threonine, are ∼100-fold diﬀerent. Likewise, the deuterium
exchange rate of the hydrogen atom of the diﬂuorophenylala-
nine moieties in compounds 1a and 1e diﬀered by 2.8-fold. As
expected, inclusion of both pipecolate and allo-threonine (1f)
into the peptidolactone had a synergistic eﬀect on deuterium
exchange. Interestingly, the apparent relationship between
rigidifying structural features and deuterium exchange rate
was not completely conserved when 4-methylpipecolate and
allo-threonine were present together in the peptidolactone
(1g). This compound had a faster rate of deuterium exchange
than compounds with allo-threonine and either N-methyl-
alanine (1e) or pipecolate (1f) in the peptidolactone. A
reasonable explanation for this observation is that substituted
pipecolate residues and allo-threonine each stabilize slightly
diﬀerent low energy conformers. Accordingly, the opposing
forces could prevent a single, low energy conformer from being
reached. As expected, the rate of deuterium exchange increased
for all compounds at an elevated temperature (i.e., 40 °C),
whereas the trend for relative rates of deuterium exchange
remained the same (see Supporting Information), suggesting
that the observed eﬀects are the result of entropic factors.
Overall, the general trend represented by these data supports
our hypothesis that the incorporation of conformationally
constrained residues in the peptidolactone has a rigidifying
eﬀect.
In Vitro Assessment of ClpP Binding and Activation
by the Rigidiﬁed ADEPs. Binding of either the ADEPs or the
regulatory ATPases to ClpP stabilizes an open conformation of
the peptidase pore and stimulates degradation of oligopep-
tides.10,39,40 On the basis of predictions that the entropic costs
of ClpP binding would be lower for the conformationally
constrained ADEP derivatives,27,29 we expected that ADEP
modiﬁcations that enhance macrocycle rigidity would improve
ClpP binding and activation in a commensurate fashion. To test
this hypothesis, we assayed ClpP catalyzed hydrolysis of an
internally quenched ﬂuorogenic decapeptide in the absence and
Figure 4. ADEP hydrogen−deuterium exchange in CD3OD.
Deuterium exchange rates were measured for 2 mM solutions of
each ADEP under pseudo-ﬁrst order conditions in deuterated
methanol at 25 °C. The exchange rates for the hydrogen atoms of
the alanine residues within the peptidolactone are shown.
Figure 5. Activation of ClpP and competition with ClpX by ADEPs in
vitro. (A) Rigidiﬁed ADEPs are more potent activators of ClpP peptide
cleavage. Hydrolysis of a ﬂuorogenic decapeptide substrate (15 μM)
by E. coli ClpP (25 nM) was assayed in the presence of increasing
concentrations of ADEP compounds, and activity was ﬁt to a
noncooperative binding model (solid lines). Error bars represent
standard deviation among three replicates or standard error of the ﬁt.
Tighter apparent aﬃnities correlate with increased ADEP rigidity, with
the exception of compound 1d. See also Table 1. (B) ADEPs with
greater macrocycle rigidity compete more strongly with ClpX for
binding to ClpP. Fold change in ATPase activity of E. coli ClpXΔN (10
nM) in the presence of E. coli ClpP (50 nM) was assayed over
increasing concentrations of ADEPs, compared to the activity of
ClpXΔN alone, and was ﬁt as above (no ﬁt was obtained for 1d). More
rigid ADEPs better compete for binding to ClpP and, thus, more
eﬀectively relieve ClpP-mediated repression of ClpXΔN ATPase
activity (Table 1).
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presence of the ADEP derivatives. Cleavage between an
aminobenzoic acid ﬂuorophore and 2-nitrotyrosine quencher
in this substrate relieves quenching, resulting in increased
ﬂuorescence that serves as a readout of peptidase activity. The
capacities of each of the compounds to activate ClpP were
assessed across a range of concentrations, and the resulting
activities were ﬁt to yield apparent dissociation constants
(Figure 5A, Table 1). As expected, we found a generally strong
and positive correlation between the potency of the compounds
as activators of ClpP and their rigidity as assessed in the
deuterium exchange experiments. Kapp values range from 7.5
μM for compound 1a, the parental compound having the least
rigid macrocycle, to 1.1 μM for compound 1g, which possesses
a signiﬁcantly more rigid macrocycle. Interestingly, compound
1d was a weaker activator of ClpP than compounds 1b and 1c,
despite having a more rigid macrocycle. The bulky C4-
isopropyl substituent may be poorly accommodated by the
ClpP binding pocket. Nevertheless, structural modiﬁcations
that rigidify the ADEP peptidolactone can improve ClpP
activation up to ∼7-fold in vitro.
In addition to modulating the quaternary structure of the
ClpP tetradecamer, ADEPs, and the accessory ATPases share
the same binding sites and are known to compete for binding
to ClpP.30−32 As the rigidiﬁed ADEPs bound to ClpP more
tightly, we predicted that these compounds would be stronger
competitors for ATPase binding. We assayed binding
competition by exploiting the observation that E. coli ClpX
ATPase activity is depressed upon binding E. coli ClpP.39,40
Accordingly, we inferred competition from the degree to which
the ADEPs relieved depression of ATP hydrolysis by ClpX
(Figure 5B, Table 1). As expected, IC50 values correlated with
apparent aﬃnities deduced from the peptidase activation
experiments. The increased competition with ClpX also
indicates that the more rigid ADEPs bind more strongly to
their original binding site on ClpP, rather than to novel sites.
Interestingly, compound 1d did not eﬀectively compete with
ClpX, despite the observation that it activated ClpP peptidase
activity to the same extent as compound 1a. Again, this weak
suppression of ClpX ATPase activity can most likely be
ascribed to poor accommodation of the isopropyl group in the
ClpP binding pocket.
Assessment of the Bioactivities of the Conformation-
ally Constrained ADEPs in Antibacterial Assays. The
antibacterial activity of each compound was assessed against
three Gram-positive bacterial pathogens: S. aureus, S. pneumo-
niae, and E. faecalis. Minimum inhibitory concentrations
(MICs) were determined by broth microdilution assays
(Table 1). All seven synthetic ADEPs exhibited strong
antibacterial activity. There were largely positive correlations
between antibacterial activity, peptidolactone rigidity, and the
apparent ClpP aﬃnity. There were some exceptions. Com-
pound 1d, despite possessing a signiﬁcantly more rigid
peptidolactone, exhibited ClpP aﬃnity and antibacterial activity
similar to that of compound 1a. Again, the presence of the large
isopropyl substituent on the pipecolate residue most likely has a
negative eﬀect on binding to ClpP and thus antibacterial
activity. In contrast, compound 1g, bearing both a 4-
methylpipecolate residue as well as an allo-threonine residue,
was not the most rigid compound (compound 1f in Table 1),
yet it exhibited the most potent antibacterial activity in the
series. While these exceptions cannot be completely explained,
we do note that ADEPs whose amide hydrogens of the alanine
residues have half-lives of more than 20 h in the deuterium
exchange experiments have the highest ClpP aﬃnities and most
antibacterial activity against all three species of bacterial
pathogens. To the best of our knowledge, compound 1g has
the lowest MICs of any ADEP reported to date.27,29 The
antibacterial activity of 1g was 32-fold more potent against S.
aureus, 600-fold more potent against E. faecalis, and 1200-fold
more potent against S. pneumoniae than compound 1a, which
has the more ﬂexible peptidolactone of the ADEP natural
products.
■ CONCLUSION
The cyclic acyldepsipeptide antibiotics are a promising class of
antibacterial agents that act by binding and dysregulating the
activity of the ClpP peptidase. Reports by our group and others
state that the activities of these compounds can be dramatically
improved by replacing certain amino acid constituents of the
peptidolactone core structure with more conformationally
constrained counterparts.27,29 It has been proposed that
improvements in bioactivity are a consequence of these
amino acids’ capacity to stabilize a bioactive conformation of
the ADEPs, which incurs a lower entropic cost upon binding to
ClpP.29 While compelling, this proposal had very little
experimental support. Herein, we present data indicating that
replacement of selected constituent amino acids in the ADEP
peptidolactone core does indeed stabilize a bioactive con-
formation. Speciﬁcally, analyses of ADEPs harboring conforma-
tionally constrained amino acids via deuterium exchange
experiments revealed that they exhibit the same hydrogen
bonds in solution that are inferred from the crystal structures of
an ADEP in complex with ClpP. Our ﬁnding that replacement
of the N-methylalanine moiety of the ADEP natural products
Table 1. Comparison of in Vitro and in Vitro ADEP Properties
MICa
compound D exchange t1/2 ClpP Activation ClpX Competition S. aureus S. pneumoniae E. faecalis
(min) Kapp (μM) IC50 (μM) (μg/mL) (μg/mL) (μg/mL)
1a 26.1 7.5 ± 0.34 53 ± 39 0.78 0.024 0.012
1b 61.6 2.9 ± 0.077 33 ± 6.5 0.39 0.006 0.015
1c 115 3.0 ± 0.10 18 ± 4.2 0.39 0.012 0.003
1d 191 7.4 ± 0.31 no f it 1.16 0.098 0.098
1e 2500 1.3 ± 0.10 9.8 ± 3.9 0.098 0.003 0.00076
1f 10000 1.3 ± 0.067 2.9 ± 1.0 0.098 <0.00002 <0.00002
1g 1180 1.1 ± 0.060 4.7 ± 1.3 0.024 <0.00002 <0.00002
aThe bacterial concentrations (colony forming units/mL) in each well of the dilution antimicrobial susceptibility tests were as follows: S. aureus
(1.20 × 106), E. faecalis (8.5 × 104), and S. pneumoniae (3.65 × 105). The deuterium exchange rates for the hydrogen atoms of the alanine residues in
the macrocycles are shown.
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with a pipecolate attenuates deuterium exchange of only one of
the two donors (i.e., amide hydrogen of alanine) in the
hydrogen bonds, whereas the substitution of the natural serine
with allo-threonine suppresses deuterium exchange rates of
both hydrogen bond donors indicates the position of the
conformationally constrained amino acid within the macrocycle
has important eﬀects on molecular conformation. In molecules
with either one or two hydrogen bonds, the inverse correlations
between the number of constrained amino acids constituting
the peptidolactone and the rates of deuterium exchange
indicated that the amino acid substitutions lock the ADEPs
into a conformation that is compatible with ClpP binding. The
apparent enhancements of the conformationally constrained
ADEPs’ capacities to both activate ClpP and compete with its
binding to the accessory ATPase ClpX corroborate the
proposal that a bioactive conformation has been fortiﬁed.
These improvements are also consistent with the proposal that
there is a lower entropic cost in the binding of the rigidiﬁed
ADEPs to ClpP. The latter point is of particular interest
because the commonly held view that rigid ligands suﬀer a
lower entropic cost in receptor binding than ﬂexible ones41 has
recently been challenged by cases wherein there are entropic
penalties for ligand preorganization in receptor−ligand
interactions.42 In any case, the ﬁnding that ClpP activation by
the ADEPs was enhanced by up to 7-fold via the introduction
of conformational constraints, while these same changes
enhanced antibacterial activity by up to 1200-fold indicates
that there are other factors involved. A likely explanation is that
the constrained compounds are more cell-permeable. Indeed,
peptides with enforced transannular hydrogen bonds exhibit
dramatically enhanced cell-permeability and oral bioavailability
because the bonding reduces the energetic costs of desolvation
that accompanies membrane penetration in aqueous environ-
ments.43 Apparently, the conformational constraints that we
have introduced enhance the ADEPs’ intrinsic transannular
hydrogen bonding interactions that predispose them for both
ClpP binding and membrane penetration.
It is well-known that the conformational constraints of
macrocylic molecules can be further enhanced by judicious
introduction of substituents on the ring.44 In this case, it is
notable that installation of small methyl substituents profoundly
enhances the aﬃnity of a large macrocycle for its biomolecular
receptor and the molecules’ bioactivities. Although replacement
of hydrogen atoms with methyl groups is common in
structure−activity relationship (SAR) studies and medicinal
chemistry optimization programs,45 the inclusion of a methyl
group on a ligand typically is deleterious or minimally improves
receptor binding. Indeed, a recent analysis of published SAR
studies by Jorgensen and co-workers states that in 8% of cases
the inclusion of a methyl group enhances bioactivity 10-fold or
better.46 In only 0.4% of cases did molecules with an additional
methyl group have 100-fold enhanced bioactivity.46 Their
analysis also revealed that signiﬁcant improvements in
bioactivity are usually the result of the methyl group’s capacity
to ﬁll a hydrophobic environment in the receptor and to
inﬂuence the conformation of the ligand. Interestingly, the
substituent eﬀect strategy exploited in medicinal chemistry is
mirrored in the ADEP natural products themselves. Speciﬁcally,
enopeptin A, which has a 4-methylproline residue in its
macrocycle, has a 2-fold lower MIC against S. aureus, S.
pneumoniae, E. faecalis, and E. faecium than enopeptin B which
has an unsubstituted proline residue at the same position.29 In
this study, we found that the position of the methyl substituent
on the ADEP peptidolactone is very important. When
comparing the ADEPs lacking methyl substituents (compounds
1a and 1b) to analogs harboring either 4-methyl pipecolate
(compound 1c) or allo-threonine (compound 1e), we ﬁnd that
the allo-threonine residue exerts the strongest inﬂuence over
conformational dynamics, ClpP aﬃnity, and bioactivity.
Furthermore, it should be noted that inclusion of allo-threonine
in the ADEP peptidolactone improves the MIC 10-fold, while
inclusion of 4-methylproline improves the antibacterial activity
only 2-fold (as evidenced in the reported MICs of enopeptin A
and enopeptin B).29
In this case, the unique characteristics of both the small
molecule ligands and their receptor facilitated in-depth studies
of a receptor−ligand interaction. Observations and modulations
of the conformational dynamics of ADEPs were accompanied
by measurements of their aﬃnity for ClpP and antibacterial
activity. A distinguishing feature of our multifaceted study was
the use of deuterium-exchange 1H NMR experiments to assess
relative diﬀerences in conformational rigidities of the ADEPs.
We have shown that in such cases, hydrogen bonding can be
exploited to study the eﬀects of structural modiﬁcation on
conformational rigidity. We anticipate that this approach to
small molecule dynamics could be applied to studies of many
ligand−receptor interactions because many small molecules
that interact with biological macromolecules exhibit trans-
annular hydrogen bonds (especially peptides). It is a much
simpler alternative to sophisticated multidimensional NMR
experiments wherein 15N- and 13C-labeled compounds are used
to assess the dynamics of small molecules.
The ADEP analogs reported herein constituted by the
conformationally constrained amino acids allo-threonine and 4-
methylpipecolate have some of the lowest MICs ever reported
for antibacterial agents. The most potent ADEP reported prior
to this work, ADEP-4, was reported to cure S. aureus infections
in mice and S. pneumoniae infections in rats with even greater
eﬃcacy than linezolid, a clinically used drug.29 Given that our
optimized analogs have MICs against S. pneumoniae and E.
faecalis that are 200-fold lower than those reported for ADEP-4,
it is tempting to speculate that a dramatically lower and
potentially safer dose of our most potent compound could be
eﬃcacious in the treatment of infections caused by Streptococci,
Enterococci, and potentially other Gram-positive pathogens. An
added advantage of the optimized compounds reported here
with respect to drug development is that the key allo-threonine
residue is much less expensive and easier to prepare than the 4-
methylproline constituent of ADEP-4.29 The promise of these
molecules is further enhanced by the observations that peptides
with strong transannular hydrogen bonds have enhanced oral
bioavailability.43,44 Testing of these compounds in animal
models of infection is currently underway in our laboratories. In
total, our ﬁndings provide a compelling illustration of how the
pharmacological properties of natural products can be
improved by rational design.
■ EXPERIMENTAL SECTION
H-D Exchange Kinetics. NMR samples were prepared by
dissolving thoroughly dried ADEP in ampule sealed CD3OD at a
concentration of 2 mM. The ADEP in CD3OD was promptly
transferred to a clean NMR tube, purged with an argon atmosphere,
then capped and sealed with paraﬁlm before being placed into the
NMR spectrometer. Standard proton NMR spectra were acquired
periodically over the course of several hours. The integration of the
exchanging amide signal of interest was calibrated to a nonexchanging
reference peak. Each data set was normalized such that the integral of
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the amide signal of interest in the ﬁrst spectrum acquired was equal to
1.00 and designated as t0. Data sets were plotted in Microsoft Excel as
normalized integrals vs time. Plotted data sets were ﬁt with exponential
curves with Y intercepts set to 1. Exchange half-lives were calculated
from the exponential functions.
Protein Expression and Puriﬁcation. E. coli ClpP bearing a C-
terminal His6 tag and single-chain pseudohexameric E. coli ClpX
ΔN
(amino acids 62−424) were expressed and puriﬁed by metal aﬃnity,
anion exchange, and gel-ﬁltration chromatography as described.39,47
Activity and Competition Assays. In vitro assays were
performed at 30 °C in PD buﬀer (25 mM HEPES, pH 7.5, 100
mM KCl, 5 mM MgCl2, 1 mM DTT, 10% (w/v) glycerol, 10% (v/v)
DMSO) using a SpectraMax M5 microplate reader (Molecular
Devices). Peptidase activation was measured by incubating 25 nM of
ClpP tetradecamer and each ADEP analog with 15 μM of an internally
quenched ﬂuorogenic peptide substrate, Abz-KASPVSLGYNO2D,48
incorporating a 2-aminobenzoic acid (Abz) ﬂuorophore and 3-
nitrotyrosine (YNO2) quencher. Peptide hydrolysis by ClpP was
monitored by following the increase in 420 nm ﬂuorescence upon 320
nm excitation. Initial analysis of peptidase data showed negligible
cooperativity; thus, data were ﬁt to a quadratic form of a
noncooperative binding equation, assuming 14 equivalent ADEP
binding sites per ClpP tetradecamer.
To assay ADEP competition for ClpX binding to ClpP, 50 nM of
ClpP tetradecamer, 10 nM of ClpXΔN pseudohexamer, 0−100 μM of
ADEP and 2.5 of mM ATP were incubated with an NADH-coupled
ATP regeneration system.49 ATP hydrolysis was monitored by
following the coupled disappearance of NADH, via decrease in 340
nm absorbance. Pseudohexameric ClpXΔN is functionally identical to
monomerically encoded ClpXΔN,39,44a and was used to ensure hexamer
stability at low ClpX concentrations. ATPase data were ﬁt as above,
assuming two ClpX binding sties per ClpP tetradecamer.
MIC Determinations. MIC determinations were performed in
BSL2+ conditions at the New England Center for Research Excellence
(NERCE) in Biodefense at Harvard Medical School following
standard dilution antimicrobial susceptibility testing protocols.50
Following incubation with the bacteria and the compound, each well
was visually examined for growth with the unaided eye. The MIC is
determined to be the ﬁrst set of replicate wells of the dilution series
exhibiting no growth when compared to the growth control wells.
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